You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
東曜藥業-B(01875.HK)中期營收大增687%至1.82億元,戰略轉型初見成效,虧損同比大幅縮減86%
格隆匯 08-13 00:02

格隆匯8月13日丨東曜藥業-B(01875.HK)發佈截至2022年6月30日止六個月中期業績,公司營業收入達人民幣1.82億元,同比增長687%,主要來自樸欣汀良好的銷售業績、快速成長的CDMO業務以及產品授權金收入。其中,產品銷售收入達人民幣1.04億元,佔集團營業收入的57%;CDMO服務收入達人民幣2,266萬元,同比增長94%;及授權金收入達人民幣4,943萬元,得益於樸欣汀及TAB014(抗VEGF單抗)的商業化合作。淨虧損同比縮減86%至人民幣1,572萬元。

期間兩項重點臨牀項目達成里程碑,集團完成TAA013的III期臨牀試驗受試者入組及TAB014的III期臨牀試驗首例受試者入組。集團將繼續負責臨牀階段產品供應及未來上市商業化生產。

此外,集團加速擴建ADC中試原液生產車間和ADC商業化製劑車間,分別計劃在2022年下半年及2023年上半年投產。

為了進一步強化公司在創新藥研發方面的技術優勢,東曜藥業積極推進全球研發中心建設工程,建設主體預計2023年落成,總建築面積達25,000平方米,將具備早期研發、工藝開發、質量研究以及總部辦公等功能。其中,研發核心實驗區域可容納280-300名科研人員,能夠同時開展多個單抗藥物、ADC藥物、溶瘤病毒藥物及特殊小分子抗腫瘤藥物的研究和工藝開發等研究工作,並和生產區域實現無縫連接,研發生產一地化也將實現藥品開發全流程的協同高效,從而提升研發效率和成本優勢。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account